Key facts
- This page summarizes Jigar Raythatha's Form 4 filing for Jounce Therapeutics, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 May 2023, 07:45.
Jigar Raythatha - 03 May 2023 Form 4 Insider Report for Jounce Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 03 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 May 2023, 07:45:13 UTC
- Prior SEC filing
- 28 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Caroline Gammill, as attorney-in-fact for Jigar Raythatha
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jigar Raythatha filed Form 4 for Jounce Therapeutics, Inc. on 04 May 2023.
Change
- Previous filing in this sequence was filed on 28 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JNCE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -31,400
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,400
- Exercise price
- $6.47
- Footnotes
- F1, F2
JNCE
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -20,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $2.80
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jigar Raythatha is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time").
Footnote F2
Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.